Continued Optimization of Low-Density Foam-Reinforced Ablatives for High-Velocity, High Heat Flux Earth Return Missions

Period of Performance: 01/01/2013 - 12/31/2013

$125K

Phase 1 SBIR

Recipient Firm

Ultramet
12173 Montague Street Array
Pacoima, CA 91331
Principal Investigator
Firm POC

Abstract

In previous work for NASA, Ultramet and ARA Ablatives Laboratory developed and demonstrated advanced foam-reinforced carbon/phenolic ablators that offer substantially increased performance under high heat flux conditions and reduced weight relative to conventional ablators. The two-piece structure consisted of an ablative-filled foam front surface backed by Ultramet's previously established and highly insulating aerogel-filled foam. Arcjet testing was performed at NASA Ames Research Center to heat flux levels exceeding 1000 W/cm2, with the results showing a significantly reduced ablation rate compared to conventional chopped fiber ablators, and ablation behavior comparable to FM5055 at just one-third the density. It is apparent that the foam helps retain the char layer by physical reinforcement and/or that the network of interconnected passages allows pyrolysis gases to escape with less disruption of the char layer. In this project, Ultramet will team with ARA Ablatives for ablative infiltration of Ultramet foams and Materials Research and Design for ablation analysis, to continue optimization of foam-reinforced ablatives by focusing on two primary areas. The ablator formulation infiltrated into the foam will be modified to maximize heat flux capability consistent with NASA Earth return requirements (1500-2500 W/cm2), and a single-piece foam TPS structure will be developed rather than separate ablative- and aerogel-filled foam sections. Preliminary mechanical and thermal testing will be performed to support design and analysis and, depending on availability, initial ablation tests may be conducted at the Sandia Solar Tower Facility. High heat flux testing at the Air Force LHMEL facility or alternative would be performed in Phase II.